Biotech News
Related news
KNSAKiniksa2026-09-04 20:01 EST
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
KNSAKiniksa2026-10-22 20:01 EST
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
ELDNEledon Pharmaceuticals, Inc.2026-09-09 11:00 EST
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
XFORX4 Pharmaceuticals2026-09-09 11:00 EST
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
INMBINmune Bio2026-09-09 12:00 EST
INmune Bio to Present at the H.C. Wainwright Global Investment Conference
CLDXCelldex Therapeutics2026-09-08 20:01 EST
Celldex to Present at Upcoming Investor Conference
GPCRStructure Therapeutics2026-11-04 12:30 EST
Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
REGNRegeneron Pharmaceuticals2026-11-02 21:05 EST
Regeneron Announces Investor Conference Presentations
BNTXBioNTech2026-10-20 10:45 EST
BioNTech veröffentlicht am 3. November 2026 Ergebnisse für das dritte Quartal 2026 und informiert über operativen Fortschritt
SABSSAB Biotherapeutics2026-10-14 12:30 EST
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
Kiniksa
IL-1 Cardiovascular Franchise Kiniksa Pharmaceuticals develops and commercializes therapies for diseases with strong biological rationale, with an emphasis on cardiovascular inflammation. Its portfolio is centered on blocking interleukin-1 alpha and beta signaling. ARCALYST ARCALYST, or rilonacept, is a weekly subcutaneous IL-1 cytokine...
Recent company news
KNSAKiniksa2026-10-27 11:30 EST
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
KNSAKiniksa2026-10-22 20:01 EST
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
KNSAKiniksa2026-09-04 20:01 EST
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
KNSAKiniksa2026-08-07 20:01 EST
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
KNSAKiniksa2026-07-28 11:30 EST
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
Stock data
- Close
- 88.34 USD
- Market cap
- 3.61B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States